Terms: = Breast cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Prognosis
23 results:
1. Therapeutic effect and metabolic fingerprinting of triple-negative breast cancer cells following exposure to a novel pH-responsive, gambogic acid-loaded micelle.
Da M; Li S; Yang R; Jia Z; Ma Y; Qi F; Zhao J; Shen G; Chen D
Nanotechnology; 2023 Dec; 35(11):. PubMed ID: 38081078
[TBL] [Abstract] [Full Text] [Related]
2. Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes.
Jing Z; Li Y; Song J; Zang X
Int J Biol Macromol; 2023 Dec; 253(Pt 3):126912. PubMed ID: 37722648
[TBL] [Abstract] [Full Text] [Related]
3. Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for breast cancer.
Kajiwara Y; Iwamoto T; Zhu Y; Kochi M; Shien T; Taira N; Doihara H; Toyooka S
Acta Med Okayama; 2022 Aug; 76(4):399-408. PubMed ID: 36123154
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic breast cancer Treated with Trastuzumab-Based Regimens.
Kourea HP; Dimitrakopoulos FI; Koliou GA; Batistatou A; Papadopoulou K; Bobos M; Asimaki-Vlachopoulou A; Chrisafi S; Pavlakis K; Chatzopoulos K; Galani E; Pentheroudakis G; Pectasides D; Bafaloukos D; Res E; Papakostas P; Koutras A; Kotoula V; Fountzilas G
Cancer Res Treat; 2022 Oct; 54(4):1053-1064. PubMed ID: 34793664
[TBL] [Abstract] [Full Text] [Related]
5. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
[TBL] [Abstract] [Full Text] [Related]
6. Contactin 1: An Important and Emerging Oncogenic Protein Promoting cancer Progression and Metastasis.
Gu Y; Li T; Kapoor A; Major P; Tang D
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32752094
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Value of Lymphangiogenesis Determinants in Luminal and Non-luminal breast Carcinomas.
Widodo I; Dwianingsih EK; Utoro T; Anwar SL; Aryandono T; Soeripto S
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2461-2467. PubMed ID: 30255700
[TBL] [Abstract] [Full Text] [Related]
8. Inflammatory Role of cancer-Associated Fibroblasts in Invasive breast Tumors Revealed Using a Fibrous Polymer Scaffold.
Balachander GM; Talukdar PM; Debnath M; Rangarajan A; Chatterjee K
ACS Appl Mater Interfaces; 2018 Oct; 10(40):33814-33826. PubMed ID: 30207687
[TBL] [Abstract] [Full Text] [Related]
9. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in breast cancer Cohorts.
Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
[No Abstract] [Full Text] [Related]
10. Neuropilin-1 Associated Molecules in the Blood Distinguish Poor prognosis breast cancer: A Cross-Sectional Study.
Naik A; Al-Zeheimi N; Bakheit CS; Al Riyami M; Al Jarrah A; Al Moundhri MS; Al Habsi Z; Basheer M; Adham SA
Sci Rep; 2017 Jun; 7(1):3301. PubMed ID: 28607365
[TBL] [Abstract] [Full Text] [Related]
11. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and flt4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract] [Full Text] [Related]
12. Novel peptides suppress VEGFR-3 activity and antagonize VEGFR-3-mediated oncogenic effects.
Chang YW; Su CM; Su YH; Ho YS; Lai HH; Chen HA; Kuo ML; Hung WC; Chen YW; Wu CH; Chen PS; Su JL
Oncotarget; 2014 Jun; 5(11):3823-35. PubMed ID: 25003617
[TBL] [Abstract] [Full Text] [Related]
13. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.
Quagliata L; Klusmeier S; Cremers N; Pytowski B; Harvey A; Pettis RJ; Thiele W; Sleeman JP
Clin Exp Metastasis; 2014 Mar; 31(3):351-65. PubMed ID: 24379135
[TBL] [Abstract] [Full Text] [Related]
15. A transcriptome signature of endothelial lymphatic cells coexists with the chronic oxidative stress signature in radiation-induced post-radiotherapy breast angiosarcomas.
Hadj-Hamou NS; Laé M; Almeida A; de la Grange P; Kirova Y; Sastre-Garau X; Malfoy B
Carcinogenesis; 2012 Jul; 33(7):1399-405. PubMed ID: 22532251
[TBL] [Abstract] [Full Text] [Related]
16. Lymphatic microvessel density, VEGF-C, and VEGFR-3 expression in different molecular types of breast cancer.
Raica M; Cimpean AM; Ceausu R; Ribatti D
Anticancer Res; 2011 May; 31(5):1757-64. PubMed ID: 21617236
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract] [Full Text] [Related]
19. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases.
Bando H; Weich HA; Horiguchi S; Funata N; Ogawa T; Toi M
Oncol Rep; 2006 Mar; 15(3):653-9. PubMed ID: 16465426
[TBL] [Abstract] [Full Text] [Related]
20. VEGF-C expression in breast cancer: clinical importance.
Yavuz S; Paydas S; Disel U; Zorludemir S; Erdogan S
Adv Ther; 2005; 22(4):368-80. PubMed ID: 16418144
[TBL] [Abstract] [Full Text] [Related]
[Next]
